Randomised, double-blind, placebo-controlled trials of non-individualised homeopathic treatment: systematic review and meta-analysis

被引:82
|
作者
Mathie, Robert T. [1 ]
Ramparsad, Nitish [2 ]
Legg, Lynn A. [3 ]
Clausen, Juergen [4 ]
Moss, Sian [1 ]
Davidson, Jonathan R. T. [5 ]
Messow, Claudia-Martina [2 ]
McConnachie, Alex [2 ]
机构
[1] Homeopathy Res Inst, London, England
[2] Univ Glasgow, Inst Hlth & Wellbeing, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[3] Univ Strathclyde, Dept Biomed Engn, Glasgow, Lanark, Scotland
[4] Karl & Veronica Carstens Stiftung, Essen, Germany
[5] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA
关键词
Non-individualised homeopathy; Meta-analysis; Randomised controlled trials; Sensitivity analysis; Systematic review; PUBLICATION BIAS; EFFICACY; FILL; TRIM;
D O I
10.1186/s13643-017-0445-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: A rigorous systematic review and meta-analysis focused on randomised controlled trials (RCTs) of non-individualised homeopathic treatment has not previously been reported. We tested the null hypothesis that the main outcome of treatment using a non-individualised (standardised) homeopathic medicine is indistinguishable from that of placebo. An additional aim was to quantify any condition-specific effects of non-individualised homeopathic treatment. Methods: Literature search strategy, data extraction and statistical analysis all followed the methods described in a pre-published protocol. A trial comprised 'reliable evidence' if its risk of bias was low or it was unclear in one specified domain of assessment. 'Effect size' was reported as standardised mean difference (SMD), with arithmetic transformation for dichotomous data carried out as required; a negative SMD indicated an effect favouring homeopathy. Results: Forty-eight different clinical conditions were represented in 75 eligible RCTs. Forty-nine trials were classed as 'high risk of bias' and 23 as 'uncertain risk of bias'; the remaining three, clinically heterogeneous, trials displayed sufficiently low risk of bias to be designated reliable evidence. Fifty-four trials had extractable data: pooled SMD was -0.33 (95% confidence interval (CI) -0.44, -0.21), which was attenuated to -0.16 (95% CI -0.31, -0.02) after adjustment for publication bias. The three trials with reliable evidence yielded a non-significant pooled SMD: -0.18 (95% CI -0.46, 0.09). There was no single clinical condition for which meta-analysis included reliable evidence. Conclusions: The quality of the body of evidence is low. A meta-analysis of all extractable data leads to rejection of our null hypothesis, but analysis of a small sub-group of reliable evidence does not support that rejection. Reliable evidence is lacking in condition-specific meta-analyses, precluding relevant conclusions. Better designed and more rigorous RCTs are needed in order to develop an evidence base that can decisively provide reliable effect estimates of non-individualised homeopathic treatment.
引用
收藏
页数:28
相关论文
共 50 条
  • [41] Adjunctive intranasal oxytocin for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
    Zheng, Wei
    Zhu, Xiao-Min
    Zhang, Qing-E
    Yang, Xin-Hu
    Cai, Dong-Bin
    Li, Lu
    Li, Xian-Bin
    Ng, Chee H.
    Ungvari, Gabor S.
    Ning, Yu-Ping
    Xiang, Yu-Tao
    SCHIZOPHRENIA RESEARCH, 2019, 206 : 13 - 20
  • [42] Soy intake is associated with lowering blood pressure in adults: A systematic review and meta-analysis of randomized double-blind placebo-controlled trials
    Mosallanezhad, Zahra
    Mahmoodi, Marzieh
    Ranjbar, Sara
    Hosseini, Razieh
    Clark, Cain C. T.
    Carson-Chahhoud, Kristin
    Norouzi, Zahra
    Abbasian, Ali
    Sohrabi, Zahra
    Jalali, Mohammad
    COMPLEMENTARY THERAPIES IN MEDICINE, 2021, 59
  • [43] Vortioxetine vs placebo in major depressive disorder: A systematic review and meta-analysis of double-blind, randomized, placebo-controlled, phase 3 trials in Japan
    Kishi, Taro
    Sakuma, Kenji
    Okuya, Makoto
    Matsuda, Yuki
    Iwata, Nakao
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2020, 74 (05) : 330 - 332
  • [44] Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials
    Lang-Illievich, Kordula
    Klivinyi, Christoph
    Lasser, Christian
    Brenna, Connor T. A.
    Szilagyi, Istvan S. S.
    Bornemann-Cimenti, Helmar
    NUTRIENTS, 2023, 15 (06)
  • [45] Blonanserin for schizophrenia: Systematic review and meta-analysis of double-blind, randomized, controlled trials
    Kishi, Taro
    Matsuda, Yuki
    Nakamura, Hiroshi
    Iwata, Nakao
    JOURNAL OF PSYCHIATRIC RESEARCH, 2013, 47 (02) : 149 - 154
  • [46] Double-blinded randomised placebo-controlled clinical trial of individualised homeopathic treatment of hyperthyroid cats
    Bodey, A. L.
    Almond, C. J.
    Holmes, M. A.
    VETERINARY RECORD, 2017, 180 (15) : 377 - +
  • [47] LECITHIN IN THE TREATMENT OF MANIA - DOUBLE-BLIND, PLACEBO-CONTROLLED TRIALS
    COHEN, BM
    LIPINSKI, JF
    ALTESMAN, RI
    AMERICAN JOURNAL OF PSYCHIATRY, 1982, 139 (09): : 1162 - 1164
  • [48] N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials
    Kishi, Taro
    Miyake, Nobumi
    Okuya, Makoto
    Sakuma, Kenji
    Iwata, Nakao
    PSYCHOPHARMACOLOGY, 2020, 237 (11) : 3481 - 3487
  • [49] N-acetylcysteine as an adjunctive treatment for bipolar depression and major depressive disorder: a systematic review and meta-analysis of double-blind, randomized placebo-controlled trials
    Taro Kishi
    Nobumi Miyake
    Makoto Okuya
    Kenji Sakuma
    Nakao Iwata
    Psychopharmacology, 2020, 237 : 3481 - 3487
  • [50] Effectiveness of a Classical Homeopathic Treatment in Atopic Eczema. A Randomised Placebo-Controlled Double-Blind Clinical Trial
    Siebenwirth, Joachim
    Luedtke, Rainer
    Remy, Wolfgang
    Rakoski, Juergen
    Borelli, Siegfried
    Ring, Johannes
    FORSCHENDE KOMPLEMENTARMEDIZIN, 2009, 16 (05): : 315 - 323